Puma Biotechnology Awards Stock Units to Attract Talent and Advance Cancer Research

Puma Biotechnology Reinforces Commitment to Innovation with New Inducement Award

Puma Biotechnology, Inc., a biopharmaceutical company dedicated to advancing cancer care, announces a significant step in its employee engagement strategy with the approval of an inducement restricted stock unit award for a new non-executive employee. The Compensation Committee of Puma’s board has sanctioned the award covering 7,500 shares of its common stock as part of the company’s 2017 Employment Inducement Incentive Award Plan. This initiative aims to attract and retain top talent in an increasingly competitive industry, enabling Puma to further its mission of developing innovative cancer therapies.

The vesting schedule for the awarded shares is structured to promote long-term employment, with one-third of the shares vesting on the first anniversary of the vesting commencement date, December 1, 2024, and the remaining shares vesting in increments of one-sixth every six months thereafter. Such a framework not only aligns the interests of new employees with the company's performance but also enhances employee motivation and commitment. By fostering a culture that rewards innovation and dedication, Puma aims to strengthen its position in the biopharmaceutical landscape, particularly in the realm of oncology.

Puma Biotechnology is renowned for its groundbreaking work in cancer treatment, particularly with its oral medication NERLYNX® (neratinib), which has been pivotal in treating HER2-overexpressed breast cancer. The drug has garnered FDA approval and European Commission marketing authorization for various indications, showcasing Puma's commitment to addressing unmet medical needs in oncology. The company’s recent initiatives, including the acquisition of alisertib, highlight its proactive approach to expanding its therapeutic portfolio. With clinical trials underway for both small cell lung cancer and HER2-negative breast cancer, Puma continues to advance its research efforts, emphasizing its dedication to improving cancer care through innovative solutions.

In addition to its employee incentive program, Puma Biotechnology’s ongoing clinical trials reflect its commitment to developing targeted therapies that address critical gaps in cancer treatment. The Phase II ALISCA™-Lung1 trial and the recently launched ALISCA™-Breast1 trial underscore the company's strategic focus on innovative combination therapies, as it seeks to enhance treatment efficacy for challenging cancer types.

Overall, Puma Biotechnology's recent developments signal a robust commitment to not only attracting talent but also pushing the boundaries of cancer treatment through rigorous research and development initiatives. This dual focus positions the company favorably within the biopharmaceutical industry, as it strives to make meaningful advancements in cancer care.